Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent

Healthcare is not just a sector, but a mission: Dr. Mansukh Mandaviya

With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Cipla launches knowledge sharing platform ‘Ciplamed 2.0’

CiplaMed 2.0 leverages advanced analytics and automation

Mandaviya addresses BRICS Health Minister’s meeting

Reiterates India’s commitment to the BRICS TB Research Network Initiative

Govt. passes National Dental Commission Bill, 2023

The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission

Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023

Several crucial provisions to elevate the standards of nursing education and services, enhance professional conduct, and ensure greater transparency and accountability introduced

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU